Bumetanide promotes neural precursor cell regeneration and dendritic development in the hippocampal dentate gyrus in the chronic stage of cerebral ischemia

Abstract

Bumetanide has been shown to lessen cerebral edema and reduce the infarct area in the acute stage of cerebral ischemia. Few studies focus on the effects of bumetanide on neuroprotection and neurogenesis in the chronic stage of cerebral ischemia. We established a rat model of cerebral ischemia by injecting endothelin-1 in the left cortical motor area and left corpus striatum. Seven days later, bumetanide 200 µg/kg/day was injected into the lateral ventricle for 21 consecutive days with a mini-osmotic pump. Results demonstrated that the number of neuroblasts cells and the total length of dendrites increased, escape latency reduced, and the number of platform crossings increased in the rat hippocampal dentate gyrus in the chronic stage of cerebral ischemia. These findings suggest that bumetanide promoted neural precursor cell regeneration, dendritic development and the recovery of cognitive function, and protected brain tissue in the chronic stage of ischemia.

Introduction

The subventricular and subgranular zones of the hippocampal dentate gyrus are brain regions where neurogenesis continues throughout adulthood. They can continue to produce new neurons, and form synaptic contacts with the existing neural circuitry (Danzer, 2008; Eisch et al., 2008). Robust neurogenesis alters noticeably after brain injury (Zhang et al., 2008; Zhao et al., 2008). The nervous system shows great plasticity after cerebral ischemia (Walther et al., 2009), increasing nerve regeneration, but the long-term viability of newborn neurons is relatively limited (Thored et al., 2006). These results indicate that the local microenvironment is not conducive to self repair after a stroke. It is of important clinical significance to explore new drugs with neuroprotective action against the effects of cerebral ischemia.

The Slc12a2 gene, which encodes the Na + -K + -2Cl - cotransporter 1 (NKCC1), is extensively expressed in different animals and tissues, including the cell membrane of cortical neurons of the central nervous system (Lee et al., 2010). Bumetanide is a specific antagonist of NKCC1 that can reduce the influx of chloride ions into cells of the central nervous system (Kahle and Staley, 2008). Bumetanide reduced cerebral edema and the infarct area by suppressing NKCC1 in the acute stage of cerebral ischemia (O′Donnell et al., 2004; Lu et al., 2007; Wang et al., 2014). Shulga et al. (2012) confirmed that bumetanide reduced the damage to nerve cells in rats. The above results verified that bumetanide exerted a certain neuroprotective effect in the brain. Nevertheless, the effects of bumetanide on neurogenesis and behavioral recovery in the chronic stage of cerebral ischemia in rats remain poorly understood. Therefore, we investigated the effects of bumetanide on neurogenesis and the recovery of learning and memory functions in rats with focal cerebral ischemia.

Materials and Methods

Ethics statement

All experimental protocols were approved by the Animal Ethics Committee of Medical University of China. The animal studies were performed in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, USA. Precautions were taken to minimize suffering and the number of animals used in each experiment.

Animals

Adult male Wistar rats weighing 200-250 g were provided by the Liaoning Changsheng Biotechnology Co., Ltd., Benxi, Liaoning Province, China (animal license No. SCXK (Liao) 2010-0001). The rats were housed at 18-23°C and 30-45% humidity and allowed free access to food and water in a periodically ventilated room with natural light.

Establishment of a rat model of focal cerebral ischemia by intracranial injection of endothelin 1 (ET-1)

Twenty-two rats were intraperitoneally injected with 10% chloral hydrate 350 mg/kg. On a stereotaxic apparatus, after shaving and sterilizing the skin, a median incision was made and subcutaneous tissue was removed to expose the skull. The skull and dura were drilled with a 2-mm-diameter electric drill. ET-1 (Sigma-Aldrich, St. Louis, MO, USA; purity ≥ 97%, specification 0.1 mg, solid powder) was diluted with sterile saline, 0.5 µg/µL. In accordance with anatomical atlas of the rat brain (Paxinos and Watson, 2005), ET-1 was injected at 0.5 µL/min with a microinjector into the following three points (Soleman et al., 2010): taking anterior fontanelle as a center, (1) anteroposterior = +0.7 mm, mediolateral = +2.2 mm, dorsoventral = −2.0 mm; (2) anteroposterior = +2.3 mm, mediolateral = +2.5 mm, dorsoventral = −2.3 mm; (3) anteroposterior = +0.7 mm, mediolateral = +3.8 mm, dorsoventral = −5.8 mm [Figure 1]. Points (1) and (2) were in the left cortical motor region; point (3) was in the left corpus striatum. At each point, 2 µL of drug was injected, totalling 6 µL. There was a 1-minute rest between each 1-µL injection. The needle was maintained in place for 3 minutes. After injection, the hole was covered with sterile gelfoam, and the incision was sutured. At 3 hours after injection (when the rats regained consciousness), the rats presenting the following manifestations were considered successful ischemic models: right upper limb flexion to the chest when the tail was lifted, or tilting to the right when walking, or circling to the right, for 24 consecutive hours. Physiological saline (2 µL) was injected into the same region of 18 sham-operated rats. Of the 22 rats injected with ET-1, 4 rats were excluded, because 2 rats died and 2 rats did not suffer from cerebral ischemia. The successful ischemic models were equally and randomly divided into ischemia group (ISC group) and ischemia + bumetanide group (ISC + BUM group) (n = 9). 18 sham-operated rats were equally and randomly divided into sham operation group (SHAM group) and sham operation + bumetanide group (SHAM + BUM group). {Figure 1}

Intracranial sustained administration of bumetanide with a mini-osmotic pump

Seven days after injury, NKCC1 antagonist bumetanide was injected in rats of the ISC + BUM and SHAM + BUM groups with the mini-osmotic pump (Model 2004; Alzet, Palo Alto, CA, USA). The mini-osmotic pump was immersed in 37°C sterile water overnight before implantation. Bumetanide (25 µg/µL), diluted by sterile water, was injected into the pump, which was connected to a 8-cm catheter. After anesthesia with 10% chloral hydrate, a rat was fixed in the stereotaxic apparatus (RWD Life Science, Shenzhen, China). After shaving, a 2.5-cm-long longitudinal incision was made behind the eye to expose the skull. The periosteum on the skull was exposed by bluntly shaving with tweezers before a hole was made on the lateral ventricle (anteroposterior −0.9, mediolateral +1.5) with a 1.2-mm cranial drill. A channel between the incision on the head and scapula on the back was bluntly opened with a hemostat for pump implantation. The catheter, connected to the pump, was inserted into the hole in the lateral ventricle. Dental cement was used to cover the connecting zone of the catheter base and the skull. Four minutes later, the scalp was sutured after the cement was dry. On average, 50 µg of bumetanide was pumped every day, for 21 consecutive days [Figure 2]. {Figure 2}

Morris water maze test

Nine rats from each group were given a Morris water maze test 28 days after injury. The changes in spatial learning and memory were detected with the water maze image analysis system (Beijing Shuolinyuan Technology Co., Ltd., Beijing, China). The escape latencies within 120 seconds were recorded for 3 consecutive days. The platform was removed from the pool on the last day, and the spatial probe test was conducted. The number of platform crossings within 60 seconds was recorded (Furuta et al., 1997).

Preparation of frozen sections

Thirty-one days after ischemia, rats were intraperitoneally anesthetized with 10% chloral hydrate 350 mg/kg, fixed with 150-200 mL of 4% paraformaldehyde through the heart, and then decapitated. After the skull was opened, brain tissue was fixed in 4% paraformaldehyde at 4°C overnight and stored in 30% sucrose solution (0.1 M PBS, pH 7.2-7.4) at 4°C. The fixed tisssue was embedded with an optimal cutting temperature compound, and serially sliced into 40-µm-thick coronal frozen sections with a cryostat (Model CM1900; Leica, Munich, Germany). The above sections were stored in an anti-freezing medium at −20°C for further use.

Measurement of infarct volume

The infarct volume was measured after Nissl′s staining in the ISC and ISC + BUM groups (n = 6). Serial coronal sections (40 µm thick) were collected at 1-mm intervals from +4.5 mm anterior to anterior fontanelle and −7.5 mm posterior to anterior fontanelle. The sections were soaked in distilled water, stained with aqueous solutions of cresyl violet for 10 minutes, washed with distilled water until colorless. They were differentiated with 95% alcohol for 30 seconds, rapidly dehydrated with absolute alcohol, permeabilized with xylene for 2 minutes, and mounted with neutral resin. Sections on ipsilateral and contralateral hemispheres were measured with ImageJ (NIH, Bethesda, MD, USA). The total infarct volume was calculated by the whole hemisphere area − infarct hemisphere area × the interval.

Immunofluorescence staining

Six rats were measured in each group. Using the free-floating method (Wang et al., 2015), brain sections were washed three times with 0.01 M PBS for 10 minutes each, blocked with 5% goat serum (Bioss Biotechnology, Beijing, China) for 90 minutes, incubated with Guinea pig anti-DCX polyclonal antibody (1:800; Millipore, Billerica, MA, USA) at 4°C overnight, and then washed three times with 0.01 M PBS for 10 minutes each. All samples were incubated with Alexa Fluor 488 goat anti-guinea pig IgG (1:800; Invitrogen, Carlsbad, CA, USA) at room temperature for 2 hours in the dark, and washed three times with 0.01 M PBS for 10 minutes each. Afterwards, all sections were mounted with anti-fluorescence quenching mounting medium. Five sections through the dentate gyrus of each rat were quantified with NIH ImageJ software (Kralic et al., 2005). The dendritic development of doublecortin (DCX)-positive cells in the hippocampal dentate gyrus was observed with a laser scanning confocal microscope (FV1000; Olympus, Tokyo, Japan). The three-dimensional structure of dendrites was reconstructed after a series of layers of DCX-positive cells in the Z-axis direction were magnified 200-fold under the confocal microscope. Dendrites and their branches were measured and described with NIH ImageJ software (Stumm and Höllt, 2007).

Statistical analysis

Data were expressed as the mean ± SD and analyzed with SPSS 17.0 for windows (SPSS, Chicago, IL, USA). One-way analysis of variance or repeated measures one-way analysis of variance was used to judge the statistical significance of the difference. A value of P < 0.05 was considered statistically significant.

Results

Bumetanide could not reduce the infarct size in rats with focal cerebral ischemia

ET-1 injection could evidently induce infarction. The infarct volume was similar between the ISC and BUM + ISC groups (125.8 ± 8.2 mm 3 vs. 129.8 ± 15.2 mm 3 ; P > 0.05; [Figure 3].{Figure 3}

Bumetanide promoted neural precursor cell proliferation and dendritic development in the hippocampal dentate

gyrus of rats after focal cerebral ischemia

DCX is a marker for neural precursor cells (Zhao et al., 2013). The number of DCX-positive cells and their dendritic morphology could be used to observe neural stem cell proliferation and dendritic development. Compared with the SHAM group, the number of DCX-positive cells and the total length of dendrites were significantly higher in the hippocampal dentate gyrus in the ISC group (P < 0.01). Compared with the ISC group, the number of DCX-positive cells and the total length of dendrites were significantly greater in the ISC + BUM group (P < 0.01). No significant difference in the number of DCX-positive cells and the total length of dendrites was detected between the SHAM and SHAM + BUM groups (P > 0.05; [Figure 4]. {Figure 4}

Bumetanide improved learning and memory functions in rats after focal cerebral ischemia

Compared with the SHAM and SHAM + BUM groups, escape latency was longer and the number of platform crossings was significantly less in the ISC group (P < 0.05). The escape latency was shorter and the number of platform crossings was significantly more in the ISC + BUM group than in the ISC group (P < 0.05; [Figure 5]). {Figure 5}

Discussion

Cerebral ischemia has been shown to promote nerve regeneration in the hippocampal dentate gyrus (Jin et al., 2001; Takasawa et al., 2002; Türeyen et al., 2004; Wang et al., 2011). Wurm et al. (2007) considered that cerebral ischemia contributed to the dendritic development and altered dendritic morphology in newborn nerve cells of the hippocampal dentate gyrus. We also confirmed that nerve regeneration and dendritic development appeared in the hippocampal dentate gyrus after focal cerebral ischemia. The application of bumetanide could further promote the above changes, but bumetanide did not exert its effect in sham operation, which suggested that bumetanide does not promote nerve regeneration under normal conditions. These results indicate that after cerebral ischemia, the application of bumetanide produced a microenvironment, which was beneficial to the regeneration and survival of nerve cells, exerting a neuroprotective effect.

We explored the underlying mechanism, that is to say, the presence of NKCC1 that mediates Cl− influx and KCC2 that mediates Cl− efflux on the cell membrane of the central nervous system (Kahle and Staley, 2008). KCC2 is expressed in mature neurons, whereas NKCC1 is mainly expressed in immature neurons (Vannucci and Perlman, 1997). GABA is an important neurotransmitter in the central nervous system, and plays a biological role by binding to a GABA A receptor. The ionotropic receptor GABA A is in a class of ligand-gated ion channels, and expressed on cell membranes. Because KCC2 is mainly expressed in normal mature neurons, after GABA A receptor is activated, extracellular Cl− concentration increases and membrane hyperpolarization occurs, playing the role of an inhibitory synapse (Ge et al., 2007).

Jaenisch et al. (2010) confirmed that NKCC1 expression increased, but KCC2 expression reduced after focal cerebral ischemia. After the GABA A receptor was activated, the Cl− channel on the cell membrane was opened, allowing a large influx of Cl− from the high extracellular concentration to low intracellular concentration and caused membrane depolarization; here GABA plays the role of an excitatory synapse (Nabekura et al., 2002; Blaesse et al., 2009).

A large number of neural precursor cells proliferate after cerebral ischemia, but only a few neural precursor cells differentiate further and survive for a long period (Arvidsson et al., 2002; Ohab et al., 2006; Thored et al., 2006). The expression of NKCC1 was found mainly in cell membranes of immature neurons (Jaenisch et al., 2010). Bumetanide, an antagonist of NKCC1, blocks NKCC1 on the cell membrane in the central nervous system, and reduces the influx of Cl− (Blaesse et al., 2009). Therefore, bumetanide has greater effects on regenerating neural precursor cells. NKCC1 activation-induced intracellular Cl− concentration increase is the main reason for GABA-mediated immature neuronal excitability. Depolarization of GABA A -mediated immature neurons may be the reason for the low survival rate of regenerated nerve cells after cerebral infarction.

GABA-mediated depolarization can cause nerve cell regeneration and migration (Ben-Ari, 2002; Owens and Kriegstein, 2002). However, cell membrane depolarization can lead to Ca 2+ influx (Nabekura et al., 2002; Toyoda et al., 2003). This leads to a large amount of Ca 2+ influx. Intracellular calcium overload is detrimental to cell survival. Kristián and Siesjö (1998) verified that after cerebral ischemia, increased Ca 2+ could trigger the death of nerve cells. Nerve cells begin to regenerate after cerebral infarction, but the survival rate of nerve cells is low over a longer period, which is consistent with the above mechanism. Bumetanide produces factors that are not conducive to nerve regeneration and survival, possibly by inhibiting NKCC1 and blocking GABA depolarization, but the precise mechanism remains poorly understood.

Our water maze test results demonstrated that bumetanide contributed to the recovery of learning and memory functions of rats with cerebral ischemia. It is unclear whether the regeneration of hippocampal dentate gyrus neurons is associated with learning and memory functions. Previous studies have confirmed that neural stem cells in the subventricular zone and hippocampal dentate gyrus could proliferate, migrate and differentiate into neurons and glial cells to replace damaged neurons after cerebral ischemia (Zhang et al., 2008; Zhao et al., 2008). The hippocampus is a part of the brain that is involved in learning and memory formation. The maintenance of normal hippocampus-dependent learning and memory function requires the involvement of new neurons, and nerve regeneration in the hippocampus can enhance learning and memory functions (Gould et al., 1999). Nerve regeneration probably promotes functional recovery, and plays an important role in the generation of spatial memory and object recognition memory (Broadbent et al., 2004). The above findings are consistent with our results. It remains controversial whether neurogenesis is directly associated with functional improvement (Ohab et al., 2006; Jaenisch et al., 2010; Minnerup et al., 2011).

In conclusion, bumetanide promoted nerve cell regeneration in the hippocampal dentate gyrus and dendritic development of neural precursor cells. It also improved learning and memory functions in rats with cerebral ischemia. These findings provide a theoretical basis for the application of bumetanide in the treatment of cerebral ischemia.[38]